Akcea Expands Leadership Team in Preparation for First Commercial Launch
September 05, 2017 07:00 ET
|
Akcea Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. focused on developing and commercializing drugs to treat...
Akcea and Ionis Announce Submission of New Drug Application for Volanesorsen to the U.S. FDA
August 31, 2017 07:00 ET
|
Akcea Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) focused on developing and commercializing drugs...
Akcea to Present at Wells Fargo Healthcare Conference
August 29, 2017 07:00 ET
|
Akcea Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 29, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat...
Akcea Reports Financial Results and Highlights for Second Quarter 2017
August 08, 2017 07:00 ET
|
Akcea Therapeutics, Inc.
Marketing authorization application submitted to the European Medicines Agency for the approval of volanesorsen Cash balance of approximately $300 million to fund volanesorsen launch and...